BLACK FRIDAY EARLY — BOGO 50% SITEWIDE

PT-141 (Bremelanotide): What It Is, What Research Shows, and What It Doesn't

By the Ageless Humans editorial team · Updated 2026-11-14 · 6 min read

PT-141, also called bremelanotide, is a synthetic peptide that activates melanocortin receptors in the brain. It has been studied mainly for its effects on sexual desire and arousal. In 2019 the FDA approved one specific prescription use, as an injectable sold under the brand name Vyleesi. Unlike blood-flow drugs, PT-141 acts on central nervous system signaling, so research describes it as working on desire rather than mechanics. Nausea is the most common side effect, and outside its approved prescription form it is an unregulated research chemical.

What Is PT-141 (Bremelanotide)?

PT-141 is a lab-made peptide modeled on alpha-melanocyte-stimulating hormone (alpha-MSH), a signaling molecule your body already produces. Bremelanotide is its generic drug name. PT-141 was its development code.

It came out of research on melanotan II, an earlier synthetic alpha-MSH analog investigated for skin tanning. Researchers testing melanotan II reported an unexpected effect on sexual arousal. PT-141 was then developed as a related compound aimed at that effect, with less focus on pigmentation.

Structurally, PT-141 is a short cyclic peptide, a small ring of amino acids. The ring shape makes it more stable than a straight chain. Like most peptides of this kind, it breaks down in the digestive tract, which is why clinical research has used injection or nasal delivery rather than pills. If you're new to the category, our primer on what peptides are covers how these short amino acid chains work as signals in the body.

How PT-141 Works: The Melanocortin Mechanism

PT-141 activates melanocortin receptors, mainly MC3R and MC4R, in parts of the brain involved in motivation and sexual response. That central action is what separates it from better-known options that work on blood flow.

The melanocortin system is a signaling network that helps regulate appetite, energy balance, skin pigmentation, inflammation signaling, and sexual behavior. Here is how the research describes the sequence:

  • Receptor binding: PT-141 binds melanocortin receptors, especially MC4R, in the hypothalamus.
  • Downstream signaling: Animal research suggests this activation influences dopamine release in brain regions tied to sexual motivation, such as the medial preoptic area.
  • Result: The effect studied is on desire and arousal, not on vascular mechanics.

This matters for two reasons. First, it explains why PT-141 was studied in people whose concern was low desire rather than physical function alone. Second, it explains several side effects. Melanocortin receptors are spread throughout the body, so activating them can also affect nausea pathways, blood pressure, and skin pigment cells.

What Has PT-141 Been Studied For?

The bulk of PT-141 research focuses on sexual desire and arousal, in both women and men, with one indication reaching FDA approval. Here is the research landscape in plain terms.

Premenopausal women (approved use). The largest research program was the RECONNECT phase 3 trials. Those trials studied bremelanotide in premenopausal women with a diagnosed, persistent low-desire condition that was not explained by another medical issue, medication, or relationship factors. Based on that program, the FDA approved bremelanotide in 2019 as an as-needed injection. Researchers reported improvements in self-reported desire and reductions in related distress compared with placebo. The measured differences were modest. They were not dramatic.

Men (investigated, not approved). Earlier clinical studies looked at intranasal PT-141 for male sexual function, including in men who had not responded well to blood-flow medications. Results were reported as promising in early phases. The intranasal program was later stopped, partly over blood pressure concerns, and bremelanotide is not approved for use in men.

Other melanocortin research. Because the melanocortin system also touches appetite and inflammation signaling, scientists study related compounds in those areas. That research involves other melanocortin agonists. It is not evidence for PT-141 itself, and online claims that stretch it into fat loss or general wellness go well beyond the data.

The Honest Evidence State: What Research Does and Doesn't Show

Bremelanotide is one of the few peptides in its category with completed phase 3 trials and a regulatory approval. That evidence covers a narrow population and use, and the effect sizes were moderate. Both points need to be held at once.

What the evidence supports:

  • A real, measurable effect on self-reported desire in the specific trial population, compared with placebo.
  • A well-characterized side-effect profile from large controlled trials.
  • A plausible, studied mechanism through central melanocortin receptors.

What the evidence does not support:

  • Use in men, postmenopausal women, or anyone outside the studied population. These groups are either unstudied or not approved.
  • Claims about tanning, fat loss, anti-aging, or general vitality. None of these are established for PT-141.
  • Safety of daily or frequent use. The approved label restricts how often it can be used, and long-term data on frequent dosing is limited.
  • Equivalence between the approved drug and "research peptide" vials sold online. Those products are not the same thing.

Overall, PT-141 is a legitimate pharmaceutical with a narrow, evidence-backed use. It is not a general-purpose biohacking peptide.

Side Effects and Safety Considerations

The most commonly reported side effect of bremelanotide is nausea, followed by flushing, headache, and injection-site reactions. In clinical trials, nausea was frequent enough that some participants stopped treatment.

Other documented considerations from the prescribing information and research:

  • Temporary blood pressure increase and heart rate changes after a dose. This is why the approved label is not recommended for people with uncontrolled high blood pressure or known cardiovascular disease.
  • Skin darkening (focal hyperpigmentation) on the face, gums, or breasts, reported mainly with repeated use. In some cases it may not fully resolve.
  • Drug interactions. Bremelanotide can slow stomach emptying, which may affect how some oral medications are absorbed.

These effects follow directly from the mechanism. A compound that activates melanocortin receptors broadly will touch pigmentation, nausea, and cardiovascular signaling, not only the target pathway. Anyone considering bremelanotide should talk with a licensed clinician who knows their full health history.

Prescription Drug vs. "Research Peptide": A Critical Distinction

The only legally marketed form of bremelanotide in the U.S. is the FDA-approved prescription product. Vials sold online as "PT-141 for research use only" are unregulated chemicals not intended for human use.

That distinction carries real consequences:

  • Purity and identity are unverified. Gray-market peptides may be under-dosed, contaminated, or not the stated compound at all.
  • Sterility is not guaranteed. Injectables need sterile manufacturing, and research-chemical sellers are not held to that standard.
  • No clinician oversight. The blood pressure and interaction concerns above are exactly why prescription use includes screening.

You'll also see PT-141 discussed next to other peptide categories, such as bioregulators. These are a different class of compounds with a different research history and mechanism. Our guide to what bioregulators are explains how they differ. For a quick-reference profile of PT-141 itself, see our PT-141 bremelanotide peptide page.

PT-141 vs. Blood-Flow Approaches: Why the Mechanism Matters

PT-141 acts on brain signaling tied to desire. Blood-flow approaches act on vascular mechanics. They address different parts of sexual response and are not interchangeable.

This is the most useful framework for understanding why bremelanotide drew research interest. Sexual response involves several layers:

1. Motivation and desire. These are central nervous system processes, which is where PT-141 acts. 2. Arousal signaling. This is the interplay between brain and body. 3. Physical response. This depends on vascular and tissue mechanics, which is where blood-flow drugs act.

A person whose issue sits at one layer may get little from something that targets another. That's why researchers tested PT-141 in men who had not responded well to blood-flow medication, and why its approved use centers on desire rather than mechanics.

The broader lesson applies to every peptide you'll read about: mechanism determines fit. A compound's research is only meaningful for the system it actually acts on.

The Bottom Line on PT-141

PT-141 (bremelanotide) is a well-studied melanocortin peptide with one narrow FDA-approved prescription use. It has a modest, real effect on desire in that population and a meaningful side-effect profile. It is not a general wellness or anti-aging compound, and research-grade vials are not a safe substitute for the prescription product.

If you're curious about PT-141, the honest path is a conversation with a licensed clinician. If what draws you to peptides is broader, such as supporting recovery, energy, and healthy aging, that is a different goal. It calls for different, well-sourced tools.

Related reading & products

Frequently asked questions

What is PT-141 used for?+

PT-141, or bremelanotide, is a synthetic peptide studied mainly for its effects on sexual desire and arousal. Its one FDA-approved use, approved in 2019 under the brand name Vyleesi, is as a prescription injection for premenopausal women with a specific diagnosed low-desire condition. Other uses, including use in men, have been investigated but are not approved.

How does bremelanotide work?+

Bremelanotide activates melanocortin receptors, mainly MC4R, in brain regions involved in sexual motivation. Animal research suggests this influences dopamine signaling tied to desire. Unlike blood-flow medications, it acts on the central nervous system rather than on vascular mechanics.

What are the side effects of PT-141?+

The most common reported side effect of bremelanotide is nausea. Flushing, headache, and injection-site reactions are also reported. It can temporarily raise blood pressure, and repeated use has been linked to skin darkening on areas like the face and gums. Anyone considering it should consult a licensed clinician.

Does PT-141 work for men?+

Early clinical studies investigated intranasal PT-141 for male sexual function and reported encouraging early results. That development program was discontinued, partly over blood pressure concerns. Bremelanotide is not FDA-approved for use in men.

Is PT-141 the same as melanotan II?+

No, but they are related. PT-141 was developed from research on melanotan II, a synthetic alpha-MSH analog studied for tanning, after researchers noticed effects on sexual arousal. Both act on melanocortin receptors. They are distinct compounds, and melanotan II is not an approved drug.

Is it legal to buy PT-141 online?+

In the U.S., the only legally marketed form of bremelanotide is the FDA-approved prescription product. Vials sold online as "research peptides" are unregulated, not intended for human use, and may have unverified purity, dose, or sterility. Using them carries real safety risks.

Keep reading